Liraglutide

Overall Health Benefits

• Treats diabetes [1-7]
• Lowers risk of heart disease [8-16]
• Lowers blood pressure [17-22]
• Helps lose weight [23-28]
• Accelerates wound healing [29-33]
• Prevents cancer [34-37]
• Boosts brain power [38-52]

Proven Health Benefits

Treats Diabetes

Several studies support the primary benefit of liraglutide:

1. In diabetic patients, liraglutide significantly improved blood sugar control with a low risk of hypoglycemia (abnormally low blood sugar). [1]
2. In children and adolescents with type 2 diabetes mellitus (T2D), a daily dose of liraglutide produced beneficial effects in controlling blood sugar levels. [2]
3. In patients with type 1 diabetes mellitus (T1D), liraglutide plus insulin treatment was effective at lowering blood sugar levels. [3]
4. In patients with T2D, liraglutide monotherapy or in combination with oral antidiabetic drugs was found to be efficacious and well-tolerated. [4]
5. In patients with T2D, liraglutide treatment was effective in improving the symptoms associated with diabetes. [5]
6. In overweight diabetic patients, liraglutide treatment resulted in reduced risk of complications. [6]
7. In diabetic patients undergoing intensive insulin therapy, liraglutide treatment improved blood sugar control. [7]

Lowers Risk of Heart Disease

Liraglutide has also been found to possess cardioprotective effects:

1. In patients with advanced type 2 diabetes, liraglutide therapy significantly lowered the mortality rate from cardiovascular causes. [8]
2. In diabetic patients, treatment with liraglutide was associated with reduced cases of cardiovascular-related deaths. [9]
3. In patients with type 2 diabetes, liraglutide was shown to have beneficial effects on the function of the heart’s left ventricle. [10]
4. A review of studies reported that liraglutide treatment lowered the risk of heart problems in diabetic patients. [11]
5. In diabetic patients with high cardiovascular risk, liraglutide treatment lowered the cardiovascular outcomes. [12]
6. A study showed that the use of liraglutide was associated with lower risk of major heart diseases. [13]
7. Liraglutide treatment was shown to be beneficial in patients with or without a history of heart failure. [14]
8. In diabetic patients, liraglutide administration greatly lowered the risk of major adverse cardiovascular events. [15]
9. In diabetic patients with coronary artery disease, monotherapy of liraglutide improved cardiovascular function. [16]

Lowers Blood Pressure

Liraglutide can also help lower abnormally high blood pressure:

1. A review of studies showed that liraglutide could significantly reduce blood pressure (BP). [17]
2. In diabetic patients, treatment with liraglutide successfully reduced BP and provided extra cardiovascular benefits. [18]
3. In diabetic patients, liraglutide produced systolic blood pressure (SBP) and weight reduction effects. [19]
4. In diabetic patients with or without antihypertensive medication, liraglutide treatment greatly improved their SBP. [20]
5. In Asian diabetic patients, daily administration of liraglutide resulted in significantly lowered SBP. [21]
6. In patients with type 2 diabetes, liraglutide treatment lowered SBP. [22]

Helps Lose Weight

Taking liraglutide can also help improve body composition by promoting weight loss:

1. In patients with heart failure, liraglutide treatment was shown to be effective as a weight-loss agent. [23]
2. In Asian patients, liraglutide produced weight-reducing effects. [24]
3. When combined with a healthy diet and mild exercise, liraglutide was shown to produce significant weight reduction. [25]
4. In obese Chinese patients with type 2 diabetes, daily injection of liraglutide greatly reduced their weight and waist circumference. [26]
5. In obese patients with type 2 diabetes, prolonged liraglutide treatment reduced body weight. [27]
6. In overweight adults with bodyweight-related disease, the addition of liraglutide to a healthy diet and exercise resulted in weight reduction. [28]

Accelerates Wound Healing

Liraglutide is also a great option for the treatment of non-healing wounds:

1. In diabetic mice with skin ulcers, the application of liraglutide-containing ointment improved wound healing. [29]
2. A study suggested that liraglutide can help treat diabetic foot ulcer possibly by reducing blood sugar levels. [30]
3. In patients with diabetic wounds, the application of liraglutide-loaded PLGA/gelatin electrospun nanofibrous mats accelerated the wound repair process. [31]
4. In mice, liraglutide improved wound healing and showed its potential in treating diabetic skin ulcers. [32]
5. In patients with type 2 diabetes, liraglutide treatment was associated with reduced risk of diabetes-related foot ulcer amputations. [33]

Prevents Cancer

Liraglutide has also been shown to possess potent anti-cancer properties:

1. The combined treatment of liraglutide and docetaxel (anti-cancer drug) worked synergistically in reducing the prostate cancer cells’ viability, causing cell cycle arrest, and inducing apoptosis (programmed cell death). [34]
2. A review of studies showed that liraglutide treatment resulted in reduced multiplication of breast cancer cells. [35]
3. A study reported that liraglutide treatment together with metformin produced anti-tumor effects against pancreatic cancer cells. [36]
4. In pancreatic cancer cells, liraglutide inhibited cell proliferation, migration, and invasion. [37]

Boosts Brain Power

A number of convincing studies found that liraglutide has cognitive-enhancing properties:

1. In mice, liraglutide administration produced neuroprotective effects. [38]
2. A study showed that liraglutide has beneficial effects on objective measures of cognitive function. [39]
3. In mice, liraglutide prevented the loss of brain receptors and synapses, and reversed memory impairment induced by Alzheimer’s disease (AD). [40]
4. In medication-induced diabetic mice that exhibited impaired learning and memory, liraglutide treatment attenuated these effects. [41]
5. A study showed that liraglutide can help treat AD by targeting the root cause of the disease. [42]
6. In rats with ovarian cysts, liraglutide treatment reduced memory impairment. [43]
7. In type 2 diabetic rats, liraglutide administration exerted a protective effect against brain cell damage. [44]
8. In diabetic rats with cognitive impairment, liraglutide improved learning and memory. [45]
9. In the mouse model of epilepsy, liraglutide reduced seizure susceptibility and cognitive dysfunction, and exerted neuroprotective effects. [46]
10. A study showed that liraglutide protected against diabetes-induced cognitive impairment. [47]
11. In diabetic mice, liraglutide administration improved cognitive function. [48]
12. In mice fed with a high-fat diet, liraglutide treatment improved metabolic parameters and had a beneficial effect on cognitive function. [49]
13. In a mouse model of Alzheimer’s disease, liraglutide administration significantly increased memory retention and total number of brain neurons. [50]
14. In aged mice, liraglutide reversed memory impairment and synaptic loss, and reduced plaque load. [51]
15. In diabetic patients, liraglutide slowed down memory function decline. [52]

References:

1. Ostawal A, Mocevic E, Kragh N, Xu W. Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review. Diabetes Ther. 2016;7(3):411-438. doi:10.1007/s13300-016-0180-0.
2. Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch JL, Rao P, Shehadeh N, Turan S, Weghuber D, Barrett T; Ellipse Trial Investigators. Liraglutide in Children and Adolescents with Type 2 Diabetes. N Engl J Med. 2019 Aug 15;381(7):637-646. doi: 10.1056/NEJMoa1903822. Epub 2019 Apr 28. PMID: 31034184.
3. Dimitrios P, Michael D, Vasilios K, Konstantinos S, Konstantinos I, Ioanna Z, Konstantinos P, Spyridon B, Asterios K. Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis. Curr Diabetes Rev. 2020;16(4):313-326. doi: 10.2174/1573399815666190614141918. PMID: 31203802.
4. Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther. 2009 Nov;31(11):2472-88. doi: 10.1016/j.clinthera.2009.11.034. PMID: 20109994.
5. Vilsboll T. Liraglutide: a new treatment for type 2 diabetes. Drugs Today (Barc). 2009 Feb;45(2):101-13. doi: 10.1358/dot.2009.45.2.1336104. PMID: 19343230.
6. Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, Jensen T, Jensen AK, Holst JJ, Tarnow L, Knop FK, Madsbad S, Andersen HU. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016 Mar;4(3):221-232. doi: 10.1016/S2213-8587(15)00436-2. Epub 2015 Dec 3. PMID: 26656289.
7. Varanasi A, Bellini N, Rawal D, Vora M, Makdissi A, Dhindsa S, Chaudhuri A, Dandona P. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol. 2011 Jul;165(1):77-84. doi: 10.1530/EJE-11-0330. Epub 2011 Jun 6. PMID: 21646283.
8. Mikhail N. Cardiovascular Effects of Liraglutide. Curr Hypertens Rev. 2019;15(1):64-69. doi: 10.2174/1573402114666180507152620. PMID: 29737256.
9. Howell R, Wright AM, Clements JN. Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date. Diabetes Metab Syndr Obes. 2019;12:505-512. Published 2019 Apr 17. doi:10.2147/DMSO.S174568.
10. Bizino MB, Jazet IM, Westenberg JJM, van Eyk HJ, Paiman EHM, Smit JWA, Lamb HJ. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. Cardiovasc Diabetol. 2019 Apr 30;18(1):55. doi: 10.1186/s12933-019-0857-6. Erratum in: Cardiovasc Diabetol. 2019 Aug 9;18(1):101. PMID: 31039778; PMCID: PMC6492440.
11. Duan CM, Wan TF, Wang Y, Yang QW. Cardiovascular outcomes of liraglutide in patients with type 2 diabetes: A systematic review and meta-analysis. Medicine (Baltimore). 2019 Nov;98(46):e17860. doi: 10.1097/MD.0000000000017860. PMID: 31725627; PMCID: PMC6867782.
12. Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation. 2018 Dec 18;138(25):2884-2894. doi: 10.1161/CIRCULATIONAHA.118.034516. PMID: 30566004.
13. Svanström H, Ueda P, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden. Lancet Diabetes Endocrinol. 2019 Feb;7(2):106-114. doi: 10.1016/S2213-8587(18)30320-6. Epub 2018 Dec 5. PMID: 30527909.
14. Marso SP, Baeres FMM, Bain SC, Goldman B, Husain M, Nauck MA, Poulter NR, Pratley RE, Thomsen AB, Buse JB; LEADER Trial Investigators. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. J Am Coll Cardiol. 2020 Mar 17;75(10):1128-1141. doi: 10.1016/j.jacc.2019.12.063. PMID: 32164886.
15. Brown-Frandsen K, Emerson SS, McGuire DK, Pieber TR, Poulter NR, Pratley RE, Zinman B, Ranthe MF, Grøn R, Lange M, Moses AC, Örsy P, Buse JB; DEVOTE Study Group. Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). Diabetes Obes Metab. 2019 Jun;21(6):1437-1444. doi: 10.1111/dom.13677. Epub 2019 Apr 1. PMID: 30793465; PMCID: PMC6504564.
16. Liu, Y., Jiang, X. & Chen, X. Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease. Lipids Health Dis 16, 227 (2017). https://doi.org/10.1186/s12944-017-0609-0.
17. Zhao X, Huang K, Zheng M, Duan J. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials. BMC Endocr Disord. 2019;19(1):4. Published 2019 Jan 7. doi:10.1186/s12902-018-0332-5.
18. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013 Aug;15(8):737-49. doi: 10.1111/dom.12085. Epub 2013 Mar 20. PMID: 23433305.
19. Zhao D, Liu H, Dong P. Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. Clin Exp Hypertens. 2020 Jul 3;42(5):393-400. doi: 10.1080/10641963.2019.1676771. Epub 2019 Oct 15. PMID: 31610701.
20. Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications. 2014 May-Jun;28(3):399-405. doi: 10.1016/j.jdiacomp.2014.01.009. Epub 2014 Jan 21. PMID: 24561125; PMCID: PMC4231710.
21. Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, Bhattacharyya A, Kumar A, Kim KW, Yoon KH, Bech OM, Zychma M. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*). Diabetes Obes Metab. 2011 Jan;13(1):81-8. doi: 10.1111/j.1463-1326.2010.01323.x. PMID: 21114607.
22. Du Q, Wang YJ, Yang S, Zhao YY, Han P. Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Adv Ther. 2014 Nov;31(11):1182-95. doi: 10.1007/s12325-014-0164-2. Epub 2014 Nov 12. PMID: 25388240.
23. Sharma A, Ambrosy AP, DeVore AD, Margulies KB, McNulty SE, Mentz RJ, Hernandez AF, Michael Felker G, Cooper LB, Lala A, Vader J, Groake JD, Borlaug BA, Velazquez EJ. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. ESC Heart Fail. 2018 Dec;5(6):1035-1043. doi: 10.1002/ehf2.12334. Epub 2018 Aug 17. PMID: 30120812; PMCID: PMC6300815.
24. Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, Bhattacharyya A, Kumar A, Kim KW, Yoon KH, Bech OM, Zychma M. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*). Diabetes Obes Metab. 2011 Jan;13(1):81-8. doi: 10.1111/j.1463-1326.2010.01323.x. PMID: 21114607.
25. Almarshad F. Short-term monotherapy with Liraglutide for weight management: A case study. J Family Med Prim Care. 2019;8(5):1804-1806. doi:10.4103/jfmpc.jfmpc_213_19.
26. Feng P, Yu DM, Chen LM, Chang BC, Ji QD, Li SY, Zhu M, Ding SH, Zhang BZ, Wang SL, Li HT, Lin JN, Wang MJ, Guo JC, Liu J, Liu ZD, Wu ST, Yang JH. Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Acta Pharmacol Sin. 2015 Feb;36(2):200-8. doi: 10.1038/aps.2014.136. Epub 2015 Jan 26. PMID: 25619391; PMCID: PMC4326793.
27. Mirabelli M, Chiefari E, Caroleo P, et al. Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes. Int J Environ Res Public Health. 2019;17(1):207. Published 2019 Dec 27. doi:10.3390/ijerph17010207.
28. Scott LJ. Liraglutide: a review of its use in the management of obesity. Drugs. 2015 May;75(8):899-910. doi: 10.1007/s40265-015-0408-8. PMID: 25985864.
29. Nagae K, Uchi H, Morino-Koga S, Tanaka Y, Oda M, Furue M. Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K/Akt pathway in keratinocytes. Diabetes Res Clin Pract. 2018 Dec;146:155-161. doi: 10.1016/j.diabres.2018.10.013. Epub 2018 Oct 25. PMID: 30367901.
30. Eleftheriadou I, Tentolouris A, Tentolouris N, Papanas N. Advancing pharmacotherapy for diabetic foot ulcers. Expert Opin Pharmacother. 2019 Jun;20(9):1153-1160. doi: 10.1080/14656566.2019.1598378. Epub 2019 Apr 8. PMID: 30958725.
31. Yu M , Huang J , Zhu T , Lu J , Liu J , Li X , Yan X , Liu F . Liraglutide-loaded PLGA/gelatin electrospun nanofibrous mats promote angiogenesis to accelerate diabetic wound healing via the modulation of miR-29b-3p. Biomater Sci. 2020 Aug 7;8(15):4225-4238. doi: 10.1039/d0bm00442a. Epub 2020 Jun 24. PMID: 32578587.
32. Available at https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(18)31281-6/fulltext#secst120.
33. Lu R, Yang J, Wei R, et al. Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells. PLoS One. 2018;13(6):e0198938. Published 2018 Jun 13. doi:10.1371/journal.pone.0198938.
34. Eftekhari S, Montazeri H, Tarighi P. Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line. Eur J Pharmacol. 2020 Jul 5;878:173102. doi: 10.1016/j.ejphar.2020.173102. Epub 2020 Apr 10. PMID: 32283060.
35. Zhao W, Zhang X, Zhou Z, et al. Liraglutide inhibits the proliferation and promotes the apoptosis of MCF-7 human breast cancer cells through downregulation of microRNA-27a expression. Mol Med Rep. 2018;17(4):5202-5212. doi:10.3892/mmr.2018.8475.
36. Ketan Dhatariya, Stephen C. Bain, John B. Buse, Richard Simpson, Lise Tarnow, Margit Staum Kaltoft, Michael Stellfeld, Karen Tornøe, Richard E. Pratley, the LEADER Publication Committee on behalf of the LEADER Trial Investigators

Diabetes Care Oct 2018, 41 (10) 2229-2235; DOI: 10.2337/dc18-1094.

37. Zhao H, Jiang X, Duan L, Yang L, Wang W, Ren Z. Liraglutide suppresses the metastasis of PANC-1 co-cultured with pancreatic stellate cells through modulating intracellular calcium content. Endocr J. 2019 Dec 25;66(12):1053-1062. doi: 10.1507/endocrj.EJ19-0215. Epub 2019 Aug 30. PMID: 31474673.
38. Batista AF, Forny-Germano L, Clarke JR, Lyra E Silva NM, Brito-Moreira J, Boehnke SE, Winterborn A, Coe BC, Lablans A, Vital JF, Marques SA, Martinez AM, Gralle M, Holscher C, Klein WL, Houzel JC, Ferreira ST, Munoz DP, De Felice FG. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer’s disease. J Pathol. 2018 May;245(1):85-100. doi: 10.1002/path.5056. Epub 2018 Apr 2. PMID: 29435980; PMCID: PMC5947670.
39. Mansur RB, Ahmed J, Cha DS, Woldeyohannes HO, Subramaniapillai M, Lovshin J, Lee JG, Lee JH, Brietzke E, Reininghaus EZ, Sim K, Vinberg M, Rasgon N, Hajek T, McIntyre RS. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. J Affect Disord. 2017 Jan 1;207:114-120. doi: 10.1016/j.jad.2016.09.056. Epub 2016 Oct 1. PMID: 27721184.
40. Batista AF, Forny-Germano L, Clarke JR, et al. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer’s disease. J Pathol. 2018;245(1):85-100. doi:10.1002/path.5056.
41. Yan W, Pang M, Yu Y, Gou X, Si P, Zhawatibai A, Zhang Y, Zhang M, Guo T, Yi X, Chen L. The neuroprotection of liraglutide on diabetic cognitive deficits is associated with improved hippocampal synapses and inhibited neuronal apoptosis. Life Sci. 2019 Aug 15;231:116566. doi: 10.1016/j.lfs.2019.116566. Epub 2019 Jun 13. PMID: 31201846.
42. Batista AF, Forny-Germano L, Clarke JR, Lyra E Silva NM, Brito-Moreira J, Boehnke SE, Winterborn A, Coe BC, Lablans A, Vital JF, Marques SA, Martinez AM, Gralle M, Holscher C, Klein WL, Houzel JC, Ferreira ST, Munoz DP, De Felice FG. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer’s disease. J Pathol. 2018 May;245(1):85-100. doi: 10.1002/path.5056. Epub 2018 Apr 2. PMID: 29435980; PMCID: PMC5947670.
43. Saad MA, Eltarzy MA, Abdel Salam RM, Ahmed MAE. Liraglutide mends cognitive impairment by averting Notch signaling pathway overexpression in a rat model of polycystic ovary syndrome. Life Sci. 2021 Jan 15;265:118731. doi: 10.1016/j.lfs.2020.118731. Epub 2020 Nov 6. PMID: 33160995.
44. Yang Y, Fang H, Xu G, Zhen Y, Zhang Y, Tian J, Zhang D, Zhang G, Xu J. Liraglutide improves cognitive impairment via the AMPK and PI3K/Akt signaling pathways in type 2 diabetic rats. Mol Med Rep. 2018 Aug;18(2):2449-2457. doi: 10.3892/mmr.2018.9180. Epub 2018 Jun 18. PMID: 29916537.
45. Palleria C, Leo A, Andreozzi F, Citraro R, Iannone M, Spiga R, Sesti G, Constanti A, De Sarro G, Arturi F, Russo E. Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects. Behav Brain Res. 2017 Mar 15;321:157-169. doi: 10.1016/j.bbr.2017.01.004. Epub 2017 Jan 3. PMID: 28062257.
46. Liu S, Jin Z, Zhang Y, Rong S, He W, Sun K, Wan D, Huo J, Xiao L, Li X, Ding N, Wang F, Sun T. The Glucagon-Like Peptide-1 Analogue Liraglutide Reduces Seizures Susceptibility, Cognition Dysfunction and Neuronal Apoptosis in a Mouse Model of Dravet Syndrome. Front Pharmacol. 2020 Feb 28;11:136. doi: 10.3389/fphar.2020.00136. PMID: 32184723; PMCID: PMC7059191.
47. Kong FJ, Wu JH, Sun SY, Ma LL, Zhou JQ. Liraglutide ameliorates cognitive decline by promoting autophagy via the AMP-activated protein kinase/mammalian target of rapamycin pathway in a streptozotocin-induced mouse model of diabetes. Neuropharmacology. 2018 Mar 15;131:316-325. doi: 10.1016/j.neuropharm.2018.01.001. Epub 2018 Jan 3. PMID: 29305122.
48. Zhang H, Chu Y, Zheng H, Wang J, Song B, Sun Y. Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation. Aging (Albany NY). 2020 Nov 26;13(1):525-536. doi: 10.18632/aging.202162. Epub 2020 Nov 26. PMID: 33298623; PMCID: PMC7835012.
49. Zhang H, Chu Y, Zheng H, Wang J, Song B, Sun Y. Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation. Aging (Albany NY). 2020 Nov 26;13(1):525-536. doi: 10.18632/aging.202162. Epub 2020 Nov 26. PMID: 33298623; PMCID: PMC7835012.
50. Hansen HH, Fabricius K, Barkholt P, Niehoff ML, Morley JE, Jelsing J, Pyke C, Knudsen LB, Farr SA, Vrang N. The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer’s Disease. J Alzheimers Dis. 2015;46(4):877-88. doi: 10.3233/JAD-143090. PMID: 25869785; PMCID: PMC4878312.
51. McClean PL, Hölscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology. 2014 Jan;76 Pt A:57-67. doi: 10.1016/j.neuropharm.2013.08.005. Epub 2013 Aug 21. PMID: 23973293.
52. Vadini F, Simeone PG, Boccatonda A, Guagnano MT, Liani R, Tripaldi R, Di Castelnuovo A, Cipollone F, Consoli A, Santilli F. Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. Int J Obes (Lond). 2020 Jun;44(6):1254-1263. doi: 10.1038/s41366-020-0535-5. Epub 2020 Jan 21. PMID: 31965072.